Obinutuzumab has become the first FDA-approved treatment for a rare autoimmune kidney disease, with Australian regulators already considering the same indication.
Australian regulators are considering a new indication for the blood cancer drug obinutuzumab after US authorities approved it as the first treatment specifically indicated for primary membranous nephropathy.
The Therapeutic Goods Administration accepted Roche’s application for the rare autoimmune kidney disease in August 2026, with the drug already approved locally for several haematological indications and, more recently, lupus nephritis.
Obinutuzumab (Gazyva) is approved in Australia for chronic lymphocytic leukaemia, follicular lymphoma, and as pre-treatment to reduce the risk of cytokine release syndrome associated with glofitamab.
The TGA also approved the anti-CD20 monoclonal antibody for lupus nephritis in April 2026, extending its use beyond haematological malignancies.
The latest US Food and Drug Administration approval covers adults with primary membranous nephropathy (pMN) at risk of disease progression, following positive results from the phase III MAJESTY trial.
The study found 36.1% of patients receiving obinutuzumab achieved complete remission of proteinuria at two years, compared with just 5.7% of those receiving tacrolimus (p<0.001).
Overall remission rates, including complete and partial remission, were also significantly higher with obinutuzumab at 50% versus 12.9% at 104 weeks.
The randomised, open-label trial enrolled 142 adults with pMN, with participants assigned to receive either obinutuzumab or tacrolimus.
The researchers reported that safety findings were consistent with the drug’s established profile, with no new safety signals identified.
The findings were presented at the European Renal Association Congress in June 2026 and published in the New England Journal of Medicine.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that targets B cells through direct cell death and enhanced antibody-dependent cellular cytotoxicity.
Related
Its B-cell-depleting activity has underpinned its use in haematological malignancies and is increasingly being harnessed to treat immune-mediated diseases.
Roche chief medical officer Dr Levi Garraway said the approval represented an important advance in targeting the underlying mechanisms of autoimmune kidney disease.
“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” he said.
“With Gazyva/Gazyvaro, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases.”
Primary membranous nephropathy is a rare autoimmune condition in which damage to the kidney’s glomeruli causes protein to leak into the urine, potentially leading to progressive kidney dysfunction and kidney failure.
According to Roche, up to 30% of untreated patients progress to kidney failure within 10 years. The condition is also associated with an increased risk of blood clots and cardiovascular complications.
The US approval adds to obinutuzumab’s expanding indications in immune-mediated kidney diseases, following approvals for lupus nephritis and idiopathic nephrotic syndrome.
Roche is also seeking Australian approval for systemic lupus erythematosus, with the TGA accepting that application for evaluation in April 2026.
The FDA is expected to make a decision on the same indication in December 2026.
Obinutuzumab is approved in approximately 100 countries for various haematological cancers, with its expanding use in autoimmune disease highlighting the growing applications of B-cell-directed therapies beyond oncology.



